IDEAYA Biosciences (IDYA) AI Stock Analysis

• Market Cap: $2.93B
• Dividend Yield: N/A
• Average Volume (3M): 831.85K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.43
• Revenue Growth: 5376.27%
• EPS Growth: 20.97%
• Country: US
• Employees: 131
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.94
• Shares Outstanding: 87,814,026
• 10 Day Avg. Volume: 743,550
• 30 Day Avg. Volume: 831,852
• PEG Ratio: 0.43
• Price to Book (P/B): 2.99
• Price to Sales (P/S): 13.99
• P/FCF Ratio: -41.64
• Enterprise Value/Market Cap: 0.98
• Enterprise Value/Revenue: 13.09
• Enterprise Value/Gross Profit: 13.37
• Enterprise Value/Ebitda: -23.78
• 1Y Price Target: $55.11
• Price Target Upside: 65.45% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 11
• EPS Forecast (FY): -3.94
• Revenue Forecast (FY): $35.87M

• Rating: 52 Neutral
• Price Target: $35.00 ▲(5.07% Upside)
• Action: Reiterated Date: 02/18/26
• Date: Action: Reiterated 02/18/26

The score is driven primarily by mixed financial performance—strong balance sheet strength offset by continued losses and weak cash flow quality. Technicals are a clear headwind with bearish momentum and the stock trading below key moving averages, while corporate updates provide some support via funded clinical progress despite the GSK collaboration termination. Valuation is difficult to assess due to negative earnings and no dividend.

Positive Factors

Strong balance sheet

IDEAYA’s balance sheet shows very low leverage and substantial equity, giving durable financial flexibility to fund multi-year clinical programs without immediate reliance on dilutive capital. This reduces execution risk for registrational trials and supports strategic optionality through 2–6+ months.

Diversified precision oncology pipeline

A broad pipeline across synthetic lethality, MTAP-pathway, ADCs and next‑gen targets provides multiple, independent value drivers. Multiple registrational and early‑stage programs reduce single‑asset binary risk and enhance long‑term prospects if several programs progress to registrational success.

Funded runway & partner readiness

A reported ~$1.1B cash buffer with explicit runway into 2030 materially lowers near‑term refinancing risk and enables execution of multiple registrational trials and commercial readiness activities with partner Servier for darovasertib, supporting milestone execution over the medium term.

Negative Factors

Persistent unprofitability

Despite recent revenue uptick, IDEAYA remains loss‑making with deep negative margins, indicating the company’s capital base is not yet producing returns. Continued operating losses may require further financing if clinical progress stalls, increasing dilution and long‑term shareholder risk.

Weak cash flow quality

Historical and recent cash flow metrics show meaningful burn and no operating or free cash flow contribution in 2025, signalling reliance on financing to sustain R&D. If trial timelines or costs extend, runway could erode faster than planned, constraining strategic flexibility.

Partner setback — GSK termination

The termination of the GSK collaboration returns programs to IDEAYA and removes partner funding/validation. This raises execution and commercialization burden, increases development costs and timelines, and heightens program risk absent an equivalent external development partner.

IDEAYA Biosciences Business Overview & Revenue Model

Company Description

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

How the Company Makes Money

null

IDEAYA Biosciences Financial Statement Overview

Summary

Financials are mixed: a strong, lightly levered balance sheet (very low debt and substantial equity) supports flexibility, but profitability remains weak with ongoing losses and the cash flow profile reflects heavy burn/limited self-funding despite a sharp 2025 revenue rebound.

Income Statement

Revenue is volatile but showed a sharp rebound in 2025 (annual revenue up ~180% vs. 2024) after multiple years of declines, which is a clear top-line positive. That said, profitability remains weak: the company is still loss-making, with a negative net margin in 2025 (about -52%) and large operating losses across the period. Overall, the income statement shows improving scale in the latest year, but the business is not yet demonstrating consistent earnings power.

Balance Sheet

The balance sheet is a relative strength. Leverage is very low (debt-to-equity roughly 0.5%–3.4% historically; ~2.7% in 2025), and equity is substantial (about $1.02B in 2025), supporting financial flexibility. The key weakness is continued negative returns on equity (losses), indicating the capital base is not yet generating profits.

Cash Flow

Cash flow quality is weak and inconsistent. Recent years show meaningful cash burn (operating and free cash flow deeply negative in 2021–2024), and the latest year provides no operating or free cash flow contribution (reported as 0 in 2025) alongside a -100% free cash flow growth figure. While earlier periods showed losses broadly matched by cash burn (free cash flow tracking net losses in 2021–2024), the overall profile still reflects heavy investment/consumption of cash with limited evidence of sustained self-funding operations.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	218.71M	7.00M	23.39M	50.93M	27.94M
Gross Profit	214.12M	3.17M	19.38M	48.83M	26.22M
EBITDA	-154.72M	-270.64M	-108.95M	-56.55M	-48.04M
Net Income	-113.70M	-274.48M	-112.96M	-58.66M	-49.76M
Balance Sheet
Total Assets	1.11B	1.12B	649.32M	387.97M	381.35M
Cash, Cash Equivalents and Short-Term Investments	639.39M	676.32M	525.11M	364.83M	246.77M
Total Debt	27.91M	19.17M	2.87M	3.48M	5.18M
Total Liabilities	86.39M	64.94M	28.23M	38.51M	79.83M
Stockholders Equity	1.02B	1.06B	621.09M	349.45M	301.51M
Cash Flow
Free Cash Flow	-73.47M	-251.44M	-117.59M	-90.62M	-58.42M
Operating Cash Flow	-71.10M	-247.58M	-115.22M	-87.17M	-55.78M
Investing Cash Flow	69.98M	-502.56M	-158.46M	-33.40M	-69.67M
Financing Cash Flow	29.78M	677.55M	362.72M	97.17M	145.45M

IDEAYA Biosciences Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 33.31
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDYA, the sentiment is Neutral. The current price of 33.31 is above the 20-day moving average (MA) of 33.26, below the 50-day MA of 33.83, and above the 200-day MA of 28.92, indicating a neutral trend. The MACD of 0.23 indicates Negative momentum. The RSI at 49.44 is Neutral, neither overbought nor oversold. The STOCH value of 61.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IDYA.

IDEAYA Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARQT	63 Neutral	$2.76B	-228.91	-10.26%	―	129.21%	80.35%
CELC	56 Neutral	$5.21B	-12.63	-179.00%	―	―	-40.75%
BEAM	54 Neutral	$2.58B	-34.27	-7.31%	―	-84.07%	-157.71%
IDYA	52 Neutral	$2.93B	-26.90	-11.10%	―	5376.27%	20.97%
AGIO	52 Neutral	$1.65B	―	-31.07%	―	36.26%	-158.98%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TVTX	47 Neutral	$2.49B	-67.82	-79.16%	―	114.22%	77.02%

IDEAYA Biosciences Corporate Events

IDEAYA updates precision oncology strategy at JPM 2026

On January 12, 2026, IDEAYA Biosciences posted an updated corporate presentation for investors in connection with the JPM 2026 Annual Healthcare Conference, outlining its strategy to build a leading precision oncology franchise and detailing progress across its diversified clinical pipeline. The presentation highlighted a deep portfolio that includes darovasertib for uveal melanoma approaching a planned Phase 3 initiation in the first half of 2026, MTAP-pathway programs IDE397 and IDE892, antibody drug conjugate and DNA damage repair combinations such as IDE705 and IDE849, and next-generation agents targeting Werner helicase, KAT6/7, and other difficult-to-drug targets, underscoring IDEAYA’s intent to expand its reach across multiple solid tumor indications and strengthen its competitive position in precision oncology.

The most recent analyst rating on (IDYA) stock is a Buy with a $62.00 price target. To see the full list of analyst forecasts on IDEAYA Biosciences stock, see the IDYA Stock Forecast page.

IDEAYA sets 2026 objectives to advance registrational trials

On January 11, 2026, IDEAYA Biosciences outlined its 2026 corporate objectives, highlighting plans to advance four registrational trials, including darovasertib across the uveal melanoma disease continuum and IDE849 as a monotherapy in neuroendocrine cancers, with key clinical milestones expected throughout the year. The company aims to deliver topline progression-free survival data in the first quarter of 2026 from the Phase 2/3 OptimUM-02 trial of darovasertib plus crizotinib in first-line HLA*A2‑negative metastatic uveal melanoma, complete or initiate additional Phase 3 and Phase 2 trials across metastatic, neoadjuvant, and adjuvant settings, and progress multiple ADC and MTAP-pathway programs into early-stage clinical studies, while emphasizing that its approximately $1.1 billion in cash and securities as of September 30, 2025 is expected to fund operations into 2030 and support global commercial readiness efforts with Servier for darovasertib.

The most recent analyst rating on (IDYA) stock is a Buy with a $62.00 price target. To see the full list of analyst forecasts on IDEAYA Biosciences stock, see the IDYA Stock Forecast page.